Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LTA4H | P09960 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10832371 | 0.88 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL5955117 | 0.87 | ALDH1A1 (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL1799092 | 0.86 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL3142683 | 0.86 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL8009616 | 0.85 | FFAR1 (0.58) | LTA4HMEN1KMT2AMAOBNR4A2 | |
| SCHEMBL6629474 | 0.84 | HDAC8 (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL8009658 | 0.81 | HPGD (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL810045 | 0.81 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL11117634 | 0.81 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1LTA4H | |
| SCHEMBL11453114 | 0.81 | ALDH1A1 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027332-B1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | DUAN JINGWU (US) | 2003-07-17 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5023255-A | Triazine derivatives; inhibitors exzyme 5-lipoxygenase | GLAXO GROUP LIMITED (GB) | 1991-06-11 | — | — | US | disclosed |
| US-4985427-A | LIPOXYGENASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1991-01-15 | — | — | US | disclosed |
| EP-0388165-A2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 1990-09-19 | — | — | EP | disclosed |
| EP-0340030-A2 | Triazine derivatives | GLAXO GROUP LIMITED (GB) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134827-A1 | Novel lactam metalloprotease inhibitors | ADAM9, ADAM8, ADAM17 | RAB9A 922/4885NPC1 1913/4885SMN1; SMN2 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.